Health news
Adding oleclumab or monalizumab to consolidation with durvalumab can improve clinical outcomes in patients with unresectable stage III non-small cell lung cancer (NSCLC), a phase 2 trial suggests. Combining durvalumab with oleclumab or monalizumab produced…
The Food and Drug Administration (FDA) has accepted the New Drug Application for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least 1…
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for poziotinib for use in patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2…
Nearly one-third of patients with nonoperative, node-negative non-small cell lung cancer (NSCLC) did not receive guideline-recommended treatment in a study published in the Journal of the National Comprehensive Cancer Network. Although the optimal treatment for…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021